Evidence map›Paper›PMID 41969198›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Associations of Monocyte Glucocerebrosidase with Cognition and Cholinergic Innervation in GBA1 Parkinson's Disease.

Sofie Slingerland, Sygrid van der Zee, Sven C D van Ijzendoorn, Anne C Slomp, Jeffrey M Boertien, Sanne K Meles, Arjan Kol, Marie Geerlings, Teus van Laar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sofie SlingerlandDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0001-7443-4918
Sygrid van der ZeeDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-4244-369X
Sven C D van IjzendoornDepartment of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0002-3664-1382
Anne C SlompDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jeffrey M BoertienDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Sanne K MelesDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Arjan KolArdena Bioanalysis, Assen, The Netherlands.
Marie GeerlingsArdena Bioanalysis, Assen, The Netherlands.
Teus van LaarDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Funding

Michael J. Fox Foundation for Parkinson's Research 010551
6 · The paper itself

Abstract

backgroundThe GBA1 gene encodes the lysosomal enzyme glucocerebrosidase (GCase). Parkinson's disease (PD) patients carrying a GBA1 variant (GBA-PD) exhibit faster cognitive decline, linked to cholinergic degeneration.

objectivesThe aim was to investigate whether GCase activity, measured in monocytes, correlates with cognitive dysfunction or regional brain cholinergic innervation in early-stage PD patients.

methodsA total of 137 PD patients underwent a complete neuropsychological assessment, blood sampling, brain magnetic resonance imaging, and

resultsMonocytes from GBA-PD (n = 42) patients exhibited significant lower GCase activity (P = 0.007) compared to those from non-GBA-PD individuals (n = 95). However, GCase activity did not correlate with cognition. Similarly, voxel-wise and volume-of-interest PET analyses did not reveal associations with monocytic GCase activity.

conclusionsMonocytic GCase activity does not appear to be a reliable biomarker for cognitive decline in early-stage PD and is not linked to regional cholinergic denervation. Peripheral measurements do not reflect central processes underlying cholinergic dysfunction. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

CognitionCognitive DysfunctionGlucosylceramidaseMonocytesParkinson DiseaseAgedBrainCholinergic NeuronsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsPositron-Emission TomographyGBA protein, humanGlucosylceramidase18F‐FEOBVGBA1Glucocerebrosidase

Identifiers

PMID41969198
PMCPMC13602285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.